Back to search results
NCT05799521

A Nasal Treatment for COVID-19

Active, Not Recruiting
PHASE2Ages 18–60InterventionalTreatment
Indiana University
~24 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:OptatePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in SARS-CoV-2 Levels
Measured over Immediately before and one-hour after treatment
+2 more outcomes measured

Conditions

COVID-19
Healthy

Explore related trials

COVID-19 InfectionHealthy

Where it's being run

1 sites across 1 states
Indiana1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

positive rapid COVID-19 test
Ordinal Scale for Clinical Improvement \< 3 (OSCI, Appendix 2) and/or
Fever \> 100 degree F and/or
Nasal congestion
negative rapid COVID-19 test
No known medical problems or taking any medication that, in the investigator's opinion, would make them unsuitable for participation.

Exclusion

FEV1 (Forced Exhaled Volume) \< 55% predicted on the day of study procedures
OSCI ≥ 3 (Objective Structured Clinical Exam)
Pregnancy
Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication
Pregnancy
Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication

What this trial measures

  • Change in SARS-CoV-2 LevelsImmediately before and one-hour after treatment

    SARS-CoV-2 levels will be measured in nasal wash before and one hour after Optate or placebo administration

  • Change in SNOT-22 scoreImmediately before and one-hour after treatment

    SNOT-22 scores (a validated, 22-item quality of life instrument survey) will be assessed immediately prior to Optate or placebo administration. The SNOT-22 assesses five domains (nasal, ear/facial, sleep, function and emotion) on a Likert scale from 0-5, where 0 means no problems and 5 means the worst possible problems. The total score ranges from 0-110, with higher scores indicating more severe symptoms. Scores will be reassessed one hour after administration.

  • Change in SNOT-22 scoreImmediately before and 24-hours after treatment

    SNOT-22 scores (a validated, 22-item quality of life instrument survey) will be assessed immediately prior to Optate or placebo administration. The SNOT-22 assesses five domains (nasal, ear/facial, sleep, function and emotion) on a Likert scale from 0-5, where 0 means no problems and 5 means the worst possible problems. The total score ranges from 0-110, with higher scores indicating more severe symptoms. Scores will be reassessed 24 hours after administration.